Cas9

This Protein Could Change Biotech Forever

Matthew Herper's early Forbes coverage of Cas9 — written just nine months after the landmark Doudna/Charpentier Science paper and weeks after Feng Zhang showed it worked in human cells. One of the first mass-market articles to call CRISPR a potential forever-change for biotech.